Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Net Margin (2016 - 2025)

Historic Net Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 3.04%.

  • Anika Therapeutics' Net Margin rose 980100.0% to 3.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.64%, marking a year-over-year decrease of 27600.0%. This contributed to the annual value of 39.66% for FY2024, which is 259300.0% up from last year.
  • Latest data reveals that Anika Therapeutics reported Net Margin of 3.04% as of Q3 2025, which was up 980100.0% from 2.4% recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Net Margin peaked at 17.12% during Q2 2021, and registered a low of 558.26% during Q4 2023.
  • Its 5-year average for Net Margin is 59.66%, with a median of 7.93% in 2022.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by -3522900bps in 2022, then surged by 4949400bps in 2024.
  • Over the past 5 years, Anika Therapeutics' Net Margin (Quarter) stood at 9.03% in 2021, then tumbled by -3902bps to 361.32% in 2022, then tumbled by -55bps to 558.26% in 2023, then soared by 89bps to 63.33% in 2024, then surged by 105bps to 3.04% in 2025.
  • Its last three reported values are 3.04% in Q3 2025, 2.4% for Q2 2025, and 3.5% during Q1 2025.